In an era of constant global disruptions, pharmaceutical supply chains face unprecedented challenges requiring innovative solutions. From trade tensions to logistics bottlenecks, the industry demands resilient models that ensure continuity without compromising quality or compliance.
Hari Kiran Chereddi, MD & CEO of HRV Pharma and New Horizon Global Pharma, discussed strategic approaches to supply chain resilience in a recent Chemical Today Magazine feature, highlighting how technology-driven solutions are reshaping pharmaceutical logistics.
Multi-Partner Supply Chain Strategy
Traditional single-source supply chains create vulnerabilities that modern pharmaceutical companies cannot afford. HRV's multi-partner approach distributes risk across multiple qualified manufacturers, ensuring operational continuity even during regional disruptions.
"Our strategy combines a multi-partner supply chain with a proprietary AI-native core to deliver agility, compliance, and end-to-end visibility. This tech-driven, decentralized model is key to our mission: to evolve India's role from a volume manufacturer to a strategic partner that can 'Design, Regulate, and Deliver from India.'"
Hari Kiran Chereddi, MD & CEO of HRV Pharma and New Horizon Global Pharma
AI-Native Operations
Artificial intelligence serves as the operational backbone, providing real-time visibility, predictive analytics, and automated compliance monitoring across the entire supply network. This technology integration enables proactive risk management and rapid response to market changes.
Strategic Transformation
The evolution from volume-based manufacturing to strategic partnership represents a fundamental shift in India's pharmaceutical positioning. This transformation emphasizes design capabilities, regulatory excellence, and reliable delivery rather than pure production capacity.
Industry Impact
Decentralized, technology-driven supply chains are emerging as the definitive solution for API industry resilience. Companies adopting these models gain competitive advantages through enhanced flexibility, reduced risk exposure, and improved compliance capabilities.
The future of pharmaceutical supply chains lies in intelligent networks that combine human expertise with AI-driven insights, creating systems capable of adapting to disruption while maintaining the highest standards of quality and regulatory compliance.
Read the complete analysis: Building Resilient Pharmaceutical Supply Chains - Chemical Today Magazine, September 2025
